Vir Biotechnology, Inc.·4

Feb 24, 8:27 PM ET

Friedl-Naderer Johanna 4

4 · Vir Biotechnology, Inc. · Filed Feb 24, 2023

Insider Transaction Report

Form 4
Period: 2023-02-22
Friedl-Naderer Johanna
Chief Business Officer, Global
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-02-22+70,00070,000 total
    Exercise: $27.01Exp: 2033-02-21Common Stock (70,000 underlying)
  • Award

    Common Stock

    2023-02-22+60,000150,000 total
Footnotes (2)
  • [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
  • [F2]25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION